Actively Recruiting

Age: 0 - 17Years
All Genders
ID06761261

Acute Hepatitis in Pediatrics

Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-01-07

437

Participants Needed

2

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating how acute hepatitis presents in children, focusing on the symptoms and blood test changes associated with this condition. The study aims to better understand the frequency of different symptoms, blood test abnormalities, and any complications that may arise from pediatric acute hepatitis. This observational study collects and analyzes patient data without altering standard medical care. The study observes children aged 0 to 17 years diagnosed with acute hepatitis who access Pediatric Emergency Rooms or are hospitalized. Researchers will document clinical signs, symptoms, and laboratory findings such as liver enzyme levels (AST, ALT, ALP, GGT) and coagulation markers to characterize the disease presentation and its variations by age and etiology. The study does not involve any experimental treatments or interventions. Participants will have their clinical course followed through routine medical care. Data collection includes symptoms, blood tests, and monitoring for severe outcomes like acute liver failure. The primary outcome is to describe how clinical and laboratory features vary with age and underlying causes of acute hepatitis. The study duration averages one year per participant and is conducted without interfering with normal treatment or hospital procedures.

CONDITIONS

Brief Title

Acute Hepatitis in Pediatrics

Who Can Participate

Age: 0 - 17Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 0 and 17 years (extremes included)
  • Access to Pediatric Emergency Room and/or hospitalization
  • Diagnosis of acute hepatitis
Not Eligible

You will not qualify if you...

  • Parent or guardian refuses to participate in the study
  • Mild elevation of liver enzymes (less than 5 times upper normal limit) in patient with known chronic liver disease
  • Neonatal jaundice without liver cell involvement or signs of cholestasis

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - Through study completion, an average of 1 year

Participants who have been diagnosed with acute hepatitis are observed to study the clinical and laboratory presentation and how it varies according to age group and different etiologies.

Participants have visits as needed during their care in Pediatric Emergency Room or hospitalization

Trial Site Locations

Total: 2 locations

1

Azienda USL di Bologna Ospedale Maggiore

Bologna, Italy, 40124

Actively Recruiting

2

IRCCS Azienda Ospedaliero - Universitaria di Bologna

Bologna, Italy, 40138

Actively Recruiting

Loading map...

Research Team

A

Arianna Dondi

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here